Tesofensine

06/25/2010 - "The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity. "
10/05/2009 - "Results from a phase II trial with Tesofensine for treatment of obesity are presented. "
10/01/2009 - "The initial positive findings suggest that tesofensine may be a well-tolerated long-term treatment for obesity, with minimal cardiovascular effects; this view appears to be shared by the FDA, which recently endorsed the phase III trial program for the agent."
05/01/2013 - "Tesofensine is a novel triple monoamine reuptake inhibitor which is in development for the treatment of obesity. "
06/01/2010 - "Using a rat model of diet-induced obesity (DIO), we characterized the pharmacological mechanisms underlying the appetite suppressive effect of tesofensine. "

05/01/2008 - "To assess the safety and efficacy of tesofensine, a triple monoamine reuptake inhibitor, in patients with advanced Parkinson disease (PD). "
05/01/2008 - "Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study."
02/15/2007 - "The objective of this study was to evaluate the efficacy and safety of three daily dosages of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) compared to placebo as monotherapy in early Parkinson's disease (PD). "
02/15/2007 - "Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease."
01/01/2008 - "Tesofensine is a centrally acting drug under clinical development for Alzheimer's disease, Parkinson's disease and obesity. "

06/25/2010 - "In contrast to tesofensine, the body weight of pair-fed rats returned to baseline at the end of the study, which may indicate that tesofensine stimulated energy expenditure. "
06/01/2010 - "DIO rats treated with tesofensine (2.0 mg/kg, s.c.) for 16 days showed significantly lower body weights than vehicle-treated DIO rats, being reflected by a marked hypophagic response. "
10/05/2009 - "[The effect of tesofensine on body weight and body composition in obese subjects--secondary publication]."
10/01/2009 - "In phase II clinical trials with tesofensine in obese individuals, dose-related reductions in body weight, body fat and waist circumference, as well as improvements in other obesity-related endocrine factors, were observed. "
04/01/2012 - "This study assesses the effects of chronic tesofensine treatment on food intake and body weight in association with changes in striatal dopamine D2/D3 receptor (D2/3R) availability of diet-induced obese (DIO) rats. "

12/03/2011 - "The monoaminergic re-uptake inhibitor tesofensine has also been shown to produce impressive weight loss in smaller-scale clinical studies. "
03/01/2012 - "Tesofensine (TE), an inhibitor of monoamine presynaptic reuptake, has produced twice the weight loss seen with currently marketed drugs. "
11/01/2010 - "Tesofensine (TE) is a new drug producing twice the weight loss in obese individuals as seen with currently marketed drugs. "
06/25/2010 - "In conclusion, the robust weight loss with long-term tesofensine treatment is likely due to a combined synergistic effect of appetite suppression and increased energy expenditure."
06/25/2010 - "Compared to baseline, long-term treatment with tesofensine (28 days, 1.0 or 2.5mg/kg, p.o.) resulted in a significant, dose-dependent and sustained weight loss of 5.7 and 9.9%, respectively. "

01/26/2007 - "This study was undertaken to examine the effect of sub-chronic (5 days) and chronic (14 days) administration of Tesofensine on the expression of brain derived neurotrophic factor (BDNF) and activity-regulated cytoskeleton protein (Arc) in the rat hippocampus. "
01/26/2007 - "We find that chronic, but not sub-chronic treatment with Tesofensine increases BDNF mRNA in the CA3 region of the hippocampus (35%), and Arc mRNA in the CA1 of the hippocampus (65%). "